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Variable Hypocoagulant Effect of Fish Oil Intake
in Humans
Modulation of Fibrinogen Level and Thrombin Generation
Kristof Vanschoonbeek, Marion A.H. Feijge, Martine Paquay, Jan Rosing, Wim Saris, Cornelis Kluft,
Peter L.A. Giesen, Moniek P.M. de Maat, Johan W.M. Heemskerk
Objective—The beneficial effect of dietary fish oil, rich in omega-3 polyunsaturated fatty acids (PUFAs), on cardiovascular
disease is multifactorial and may partly rely on their anticoagulant action. We studied how fish oil intake influenced
thrombin generation in plasma and which factors were involved herein.
Methods and Results—Twenty-five healthy males with borderline overweight received 3.0 g omega-3 PUFAs daily for 4
weeks. Fish oil intake reduced plasma triglycerides and lowered platelet integrin activation, as well as plasma levels of
fibrinogen and factor V, but had no effect on vitamin K-dependent coagulation factors. Before fish oil intake, thrombin
generation (reflecting the coagulant potential) considerably varied between plasmas from individual subjects, which
were partly explained by variation in prothrombin, antithrombin, fibrinogen, and factor V levels. Fish oil intake reduced
thrombin generation in the presence and absence of platelets. This reduction correlated with the fish oil effect on
fibrinogen and factor V levels. Interestingly, the lowering effect of fish oil on thrombin generation and fibrinogen
clustered around subjects with high fibrinogen carrying a structural fibrinogen -chain polymorphism.
Conclusions—Dietary omega-3 PUFAs provoke a hypocoagulant, vitamin K-independent effect in humans, the degree of
which may depend on fibrinogen level. (Arterioscler Thromb Vasc Biol. 2004;24:1734-1740.)
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Since the 1970s, fish oil has been studied as a nutritionalcomponent with antithrombotic potential.1 The protective
effect on thrombosis has been attributed to the omega-3 poly-
unsaturated fatty acids (PUFAs), eicosapentaenoic acid, and
docosahexaenoic acid, which are abundantly present in fish oil.
Early epidemiological and intervention studies pointed to a
strong association between consumption of omega-3 PUFAs and
a reduced risk of coronary heart disease, even with only 2 fish
dishes per week.2,3 Currently, a daily intake of 0.3 g of omega-3
PUFAs is recommended for healthy adults, and a daily dose up
to 1 to 3 g is recommended for patients with coronary heart
disease or hypertriglyceridemia.4
Despite 30 years of study, the precise mechanisms of
action of omega-3 PUFAs are still a matter of debate.5
Established effects include an altered heart and vessel func-
tion, a decreased risk for arrhythmias, and lowering of blood
pressure. Many reports also describe effects on plasma
hemostatic variables, but usually with high interstudy varia-
tion. Best documented is that omega-3 PUFA intake reduces
plasma triglycerides levels, whereas plasma cholesterol is
decreased in only few studies.6–8 Part of published studies
show, often mild, lowering effects of omega-3 PUFA on
platelet activation and bleeding time.9
With respect to coagulation, some trials point to a moderate
reduction by fish oil of the plasma levels of fibrinogen and
coagulation factors V, VII, and X,10–12 whereas other studies
fail to detect this.5,9 Because some of these factors require
vitamin K-dependent carboxylation for coagulant activity, it
was suggested that fish oil interferes with the vitamin K
action. In rat, we and others have found that high amounts of
dietary omega-3 PUFAs reduce the levels of the vitamin
K-dependent factors X and prothrombin.13,14 By continuous
measurement of thrombin generation, which provides a
highly sensitive method of measuring the coagulant potential
of plasma,15,16 we established that this lowering of coagula-
tion factor levels resulted in hypocoagulant activity.13 How-
ever, because this hypocoagulant effect in rat was not
enlarged by vitamin K depletion and was accompanied by a
reduction in (vitamin K-independent) factor V, the hypoco-
agulant effect of fish oil has at least a partially vitamin
K-independent cause.17 How intake of omega-3 PUFAs
influences thrombin generation in humans is still unknown.
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Genetic variation in coagulation factors and adhesive
platelet glycoprotein is likely to contribute to the risk for
arterial and venous thrombosis.18,19 There is limited evidence
that genetic variety may also contribute to the antithrombotic
response to nutrition. For instance, the reducing effect of
dietary omega-6 fatty acids on lipoprotein levels has been
found to differ between carriers of polymorphisms of several
genes encoding for apolipoproteins.20 It is therefore possible
that the hypocoagulant effect of omega-3 PUFAs is also
sensitive to gene–environmental interactions which, in turn,
contribute to the variable outcome of fish oil intervention
studies.
In the present study, we investigated the effects of fish
oil-derived omega-3 PUFAs on thrombin generation (reflect-
ing the coagulant potential) in a group of subjects with
borderline overweight and therefore slightly increased throm-
botic risk. Because thrombin generation in plasma is critically
dependent on the presence of procoagulant phospholipids,21
this process was measured in the presence of either phospho-
lipid vesicles or autologous platelets. It appeared that fish oil
intervention decreased thrombin generation even in the ab-
sence of platelets, along with coagulation factors fibrinogen
and factor V. Intriguingly, this hypocoagulant effect was
clustered in a subgroup with relatively high baseline levels of
fibrinogen who were carrying the 312A polymorphism in the
fibrinogen- gene.
Methods
Please see http://atvb.ahajournals.org for an expanded
Methods section.
Results
Effects of Fish Oil Intervention on Coagulation
Factor Levels and on Thrombin Generation in the
Presence and Absence of Platelets
Twenty-five healthy male subjects, aged 48.59.8 years
(meanSD), with borderline overweight (body mass index
29.02.5 kg/m2) participated in the fish oil study. The
intervention consisted of intake of capsules with 3.0 g
omega-3 PUFAs per day for 4 weeks, which was equivalent
to, on average, 32.8 mg omega-3 PUFAs per kg body weight
daily. Blood samples were taken 4 weeks before, immediately
before, and 4 weeks after fish oil treatment. In baseline blood
samples, all 25 subjects had normal counts of platelets
(2159109/L), erythrocytes (5.20.11012/L), and leuko-
cytes (6.60.4109/L). Fish oil intake did not affect these
parameters. The intervention resulted in significantly lower
levels of plasma triglycerides, which is a common effect of
fish oil. In contrast, cholesterol in low-density lipoprotein
tended to be increased (borderline significant; Table 1).
After earlier diet studies with rats,13,17 vitamin
K-(in)dependent coagulation factors were measured. In the
group of 25 volunteers, fish oil intake reduced plasma levels
of the vitamin K-independent coagulation factor V (signifi-
cant) and of fibrinogen (borderline significant), but not of the
vitamin K-dependent factors, prothrombin, factor VII, and
factor X (Table 1). Fibrinogen antigen level was significantly
reduced after fish oil by 4.13.1% (meanSE; P0.03)
when an EIA-based test was used instead of the activity-
based Clauss test. Anticoagulant proteins antithrombin and
protein C were not altered (Table 1).
To measure platelet activation, platelets in platelet-rich
plasma (PRP) were stimulated with the PAR1 thrombin-
receptor agonist, SFLLRN. Flow cytometric analysis indi-
cated that fish oil intake significantly lowered SFLLRN-
induced activation of IIb3 integrin (18.4%), but not
SFLLRN-provoked exposure of P-selectin, when compared
with effects of SFLLRN in pre-intervention PRP samples
(Table 2).
As a sensitive way to monitor the coagulant potential under
hypocoagulant conditions, we measured thrombin generation
in tissue factor-triggered plasma after the thrombogram meth-
od.15 To provide procoagulant phospholipids, plasma was
TABLE 1. Effect of Fish Oil on Plasma Lipid Levels and Hemostatic Parameters
No
Treatment
After
Fish Oil
No
Treatment (%)
Fish Oil
(%)
Lipids
Triglycerides (mmol/L) 1.590.23 1.330.16 2.68.3 10.45.0**
Total cholesterol (mmol/L) 5.640.25 5.700.27 2.51.7 1.11.6
LDL cholesterol (mmol/L) 3.910.26 4.070.27 2.22.9 5.73.4*
Factors
Fibrinogen (g/L) 3.390.11 3.290.13 1.21.9 2.92.0*
Prothrombin (%) 101.61.9 102.12.3 1.60.7* 0.40.9
Factor V (%) 100.83.7 97.63.8 0.91.6 3.11.5**
Factor VII (%) 102.73.0 102.53.3 1.42.0 0.31.3
Factor X (%) 103.02.2 101.82.4 0.70.9 1.20.8
Antithrombin (%) 84.11.3 83.61.2 2.01.0 0.41.2
Protein C (%) 108.52.3 110.42.7 1.61.1 1.81.3
Levels or activities (% of normal pooled plasma) were measured 4 weeks before, immediately
before, and 4 weeks after fish oil treatment. There were no systematic differences between the two
baseline samples. Shown are averaged values before treatment and values after fish oil intake, further
percent differences (calculated per subject) between pretreatment values and fish oil effect (no
treatment and fish oil). MeanSE (n25). *P0.1 and **P0.05 (Wilcoxon).
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supplied with platelets (PRP of standardized platelet count) or
with a nonlimiting concentration of 4 mol/L phospholipids
(platelet-free plasma [PFP]/phospholipids). Coagulation in
PRP was initiated with a low concentration tissue factor (0.5
pmol/L) sufficient to start intrinsic coagulation and to detect
platelet-dependent effects. Coagulation in PFP/phospholipids
was triggered with optimal tissue factor (5 pmol/L). The
thrombograms were analyzed on the following parameters:
time to thrombin peak; peak height (indicative of maximal
rate of thrombin formation); and area-under-the-curve or
endogenous thrombin potential (ETP), reflecting total activity
of thrombin during coagulation. Under these experimental
conditions with PRP or PFP/phospholipids, thrombin gener-
ation relied on the extrinsic coagulation pathway and had an
assay variability 3%.22
Before fish oil intervention, thrombin generation curves
greatly differed between plasmas from the 25 subjects, as
apparent from the high variation in thrombin peak heights and
ETP levels (Figure 1A). The intersubject variation coeffi-
cients of ETP with PRP and PFP/phospholipids (16.5% and
13.1%, respectively) were much higher than intrasubject
variation coefficients (4.5%). Typically, ETP levels in the
presence and absence of platelets were strongly correlated
with R0.48 and P0.001 (Figure 1B). Thus, those subjects
whose plasmas displayed relatively high thrombin generation
with platelets also had high thrombin generation with phos-
pholipids present (Figure 1A). This indicated that much of the
subject-dependent variability in thrombin generation with
platelets was caused by variant activity of the coagulation. No
differences were seen in thrombogram parameters between 2
plasma samples taken before the intervention (Table 2).
In addition, thrombin generation was measured in the
presence and absence of activated protein C (APC) to
determine the sensitivity of factor Va toward inactivation by
APC. This reaction is sensitive to lipid (steroid) plasma
components.23 The results were expressed as normalized APC
sensitivity ratio (nAPCsr), which by definition has a value of
1.0 in normal pooled plasma.23 Before intervention, plasmas
from the 25 subjects displayed variable nAPCsr values, with
2 subjects showing a nAPCsr 	2.5 (Figure 1C).
When averaged for all 25 subjects, thrombogram parame-
ters of PRP were significantly altered after 4 weeks of fish oil
intake. The intervention significantly prolonged the time-to-
peak and decreased the peak height and the ETP by 	10%
(Table 2). With PFP/phospholipids, fish oil prolonged the
time-to-peak and had a smaller (borderline significant) effect
on peak height and ETP of 3%. Typically, in some, but not
in all, subjects, fish oil intake resulted in a decreased
thrombin generation (Figure 2). The intervention did not
significantly influence nAPCsr, indicating that factor Va
inactivation remained unchanged. These data thus indicate
that the reducing effect of fish oil on coagulant potential in
the presence and absence of platelets is caused by reduced
thrombin formation rather than by increased APC-dependent
factor Va inactivation or increased thrombin inhibition.
Contribution of Fibrinogen and Factor V to Fish
Oil Effect on Thrombin Generation
By multivariate regression analysis, the contribution of
plasma (anti)coagulant factors to the large intersubject vari-
ation in thrombin generation was evaluated. Comparison of
pre-intervention values of the 25 subjects (Table 2) showed
that levels of prothrombin and antithrombin were main
determinants of ETP with PFP/phospholipids (R0.26,
P0.042). This is in agreement with published kinetic data.24
The levels of only fibrinogen and factor V further contributed
to the ETP variation. Together, these 4 factors explained
30% of the variation of peak height and ETP (R0.31,
P0.036). The vitamin K-dependent factor VII, factor X, and
protein C, which were covariants (P0.03), only determined
TABLE 2. Effect of Fish Oil on Platelet Activation and Thrombin Generation
No
Treatment
After
Fish Oil
No
Treatment (%)
Fish Oil
(%)
Platelet activation
aIIb3 (% pos. cells) 55.45.5 45.66.2 8.012.2 18.410.6**
P-selectin (% pos. cells) 48.12.9 44.65.0 9.210.7 3.012.8
Thrombin generation with platelets
Time-to-peak (min) 25.70.6 27.00.7 0.62.2 5.62.5*
Thrombin peak (nmol/L) 1185 1015 3.15.9 13.93.7**
ETP (nmol/Lmin) 152450 136961 0.43.0 9.83.2**
Thrombin generation with phospholipids
Time-to-peak (min) 5.60.2 5.80.2 1.62.0 4.21.7**
Thrombin peak (nmol/L) 3059 2949 2.73.1 3.02.3*
ETP (nmol/Lmin) 184748 180550 3.31.6* 2.11.6*
APC resistance
nAPCsr 1.170.16 1.200.17 6.04.9 3.84.5
Shown are averaged values before treatment and values after fish oil intake, as well as difference between these
(no treatment and fish oil). Platelets were stimulated with 5 mol/L SFLLRN and exposure of activated IIb3
integrin and of P-selectin was evaluated. Thrombin generation in plasma was measured as indicated for Figure 1.
nAPCsr was determined from thrombin generation in the presence and absence of APC. MeanSE (n25). *P0.1
and **P0.05 (Wilcoxon).
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the time-to-peak (P0.046) but did not further contribute to
peak height and ETP level.
Multiregression analysis of data from all subjects was also
used to determine whether the fish oil effect on coagulation
factor levels could explain its effect on thrombin generation.
For PFP, the fish oil-evoked reduction in ETP significantly
correlated with the reduction in fibrinogen or factor V level of
R0.48 (P0.015) or R0.41 (P0.045), respectively. The
variable decrease in thrombin peak height also correlated
with the reduction in factor V (P0.041), whereas the
increase in lag-time of thrombin formation correlated with the
reduction in fibrinogen (P0.021). Also in PRP, the inter-
vention effects on ETP and factor V level were correlated
(P0.016), but not those on ETP and fibrinogen level
(P0.77). An indication that variable fibrinogen did contrib-
ute to thrombin generation in PRP came from reanalysis of
calibrated curves; fish oil effects on thrombogram peak
height were correlated with fibrinogen level (P0.048,
n11). However, there was no correlation between the fish
oil effect on IIb3 integrin activation and on thrombin
generation in PRP (Table 2).
Control experiments were performed to determine whether
changes in fibrinogen and factor V could influence thrombo-
gram characteristics. Figure 3 shows that addition of 10%
human fibrinogen to normal pooled PFP/phospholipids re-
sulted in increased thrombin generation, as indicated by
higher thrombin peak and ETP levels. Partial depletion of
fibrinogen but not factor V led to decreased thrombin
generation. Complete depletion of factor V but not of fibrin-
ogen abolished thrombin generation.
Genetic Variation in Fibrinogen and Factor V to
Hypocoagulant Fish Oil Effect
Given the high variation in thrombograms between subjects,
we explored the possibility that genetic variation in fibrino-
gen and factor V contributed to the variable effects of fish oil
intervention on the coagulant potential. As a start, common
polymorphisms in fibrinogen-/ and factor V genes were
determined that have been associated with an increased risk
of thrombosis. With respect to the fibrinogen- gene, 11
subjects were carrying the less common allele of all the
G-854A, G-455A, and C-148T polymorphisms (1 homozy-
gous), which are known to be in linkage disequilibrium. For
these polymorphisms, we did not find associations with ETP
or fish oil effects on ETP. In contrast, 10 subjects carrying the
312Ala allele of the fibrinogen- T312A polymorphism,25
had higher baseline levels of fibrinogen and a greater reduc-
tion in fibrinogen on fish oil consumption (P0.008 and
0.021, respectively) in comparison to the 15 noncarriers
(Figure 4A). Fibrinogen reduction in the group of carriers
correlated with the decrease in thrombin generation after fish
oil (P0.048). Analysis of data from all subjects indicated
that the 312Ala carriers were responsible for the fish oil effect
on fibrinogen and thrombin generation. In the heterozygote
TA group, the average decrease in fibrinogen was 8%,
whereas in the homozygote TT group, fibrinogen increased
0.5% (Figure 4B).
Five of 25 subjects carried the less common 1299Arg allele
of the A4070G polymorphism of factor V, which is invariably
associated with the HR2 haplotype.26,27 These carriers had
lower factor V levels than noncarriers both before and after
the intervention period (P0.032 and 0.035, respectively).
They had a tendency to greater factor V reduction with fish
oil (P0.06) in comparison to noncarriers, which correlated
with the reduced thrombin generation (Figure 4C and 4D).
Two subjects carried the Gln506 (factor VLeiden) allele of the
G1691A factor V polymorphism. They were responsible for
the high nAPCsr levels 	2.5 (Figure 1C), which is in
Figure 1. Intersubject variation in thrombin generation. A, Tissue
factor-induced thrombin generation in plasma from 2 represen-
tative subjects with either 100109 platelets/L (PRP) or
4 mol/L phospholipids (PFPPL). Note the high curves for
subject A in comparison to subject B. B, Correlation between
ETP levels determined in plasma from all 25 subjects in the
presence of platelets and with phospholipids (95% CI is shown,
R0.48, P0.001). C, Normalized APC sensitivity ratio (nAPCsr)
determined in plasma from the 25 subjects. *Heterozygous fac-
tor VLeiden carriers.
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agreement with expected APC resistance,28 but they did not
show particular responses to fish oil.
With respect to platelet receptors, 12 subjects carried the
high-risk 807T variant of integrin-2, and 5 subjects carried
the Leu33 (PlA2) variant of the C1565T integrin-3 poly-
morphism. Thrombograms of PRP with or without fish oil
were not different between carriers and noncarriers
(P	0.073).
Discussion
The present data are a first report in humans on reduced
thrombin generation in response to fish oil intake. This effect
was achieved in healthy male volunteers with borderline
overweight, consuming 3.0 g fish oil-derived omega-3
PUFAs daily for 4 weeks, and it was accompanied by a
reduction in plasma levels of mainly fibrinogen and factor V.
In agreement with other studies, fish oil intake lowered the
plasma triglyceride concentrations.6 – 8 This latter effect
pointed to efficacy of the omega-3 PUFA intervention. The
intervention led to a small increase in low-density lipoprotein
cholesterol, an effect that is also not uncommon after fish oil
intervention in normal and hyperlipoproteinemic subjects.6,8
The data suggest that the reducing effects of fish oil on
tissue factor-induced thrombin generation and on fibrinogen
level are causally related. First, variability analysis shows that
fibrinogen, in addition to prothrombin, antithrombin, and
factor V, is a main coagulation factor contributing to the
intersubject variation in thrombogram parameters (peak
height and ETP). The enhancing effect of fibrinogen on
thrombin generation in situ has earlier been described by
Hemker et al.22 Second, the intervention effect on thrombin
generation in individuals significantly correlates with the
effects on fibrinogen and factor V level. This holds for
thrombograms obtained in the presence and absence of
platelets. Third, in vitro modulation of fibrinogen in normal
pooled plasma causes similar changes in thrombin generation
as the fish oil intervention. Because artificial addition or
depletion of factor V in normal plasma did not influence
thrombin generation, it is likely that factor V, in the throm-
bogram variation, is a confounder for another related plasma
factor that influences thrombin formation or inactivation. The
lack of fish oil effect on nAPCsr suggests that this concerns
a coagulant rather than anticoagulant factor.
Earlier studies often failed to measure anticoagulant effects
of fish oil consumption,29 most probably because less sensi-
tive coagulation assays like the prothrombin time were
used.15 However, in some but not all human studies, a
reduction in plasma fibrinogen and/or factor V activity was
observed in response to fish oil.9,12 In addition, in rats,
feeding of low doses of omega-3 PUFAs lowered factor V
levels.17 With respect to fibrinogen, which is likely an
independent cardiovascular risk factor when increased, fish
oil has been shown to decrease this factor mainly in subjects
with elevated baseline levels.10,11 The present data agree with
this.
At the applied dose of 3.0 g omega-3 PUFAs/d, we did not
find an intervention effect on vitamin K-dependent coagula-
tion factors, prothrombin, factor VII, factor X, and protein C.
This contradicts to the idea that fish oil can interfere with
vitamin K action, as proposed from other studies in which
factor VII and factor X were moderately reduced by fish
oil.11,12,30 In rat plasma, we and others have measured reduced
levels of prothrombin and factor X, an observation that was
compatible with vitamin K antagonistic activity.13,14 How-
ever, this was seen after relatively high doses of fish oil (3
energy%), and the hypocoagulant effect was not further
affected by vitamin K depletion.17 This strongly suggests that
the main fish oil effect, especially at lower doses, is indepen-
dent of vitamin K.
Quantitatively, the fish oil-induced decline in thrombin
generation (peak level) was greater in the presence (15%)
than in the absence (3%) of platelets. It is noted that
Figure 2. Variable effect of fish oil on
thrombin generation. Thrombograms are
given of plasma (PFPPL) before and
after fish oil intake from 2 representative
subjects with different intervention
responses (conditions as in Figure 1). For
subject C, fish oil resulted in a 20%
reduction in ETP, which was accompa-
nied by a 7% reduction in fibrinogen.
Fish oil did not alter ETP or fibrinogen in
plasma from subject D.
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relations between thrombin generation with platelets and, eg,
fibrinogen levels are more difficult to establish because of the
high intrasubject variation in the assay with PRP. Fish oil
reduced platelet integrin IIb3 activation in response to
thrombin-receptor stimulation. This is compatible with the
notion that thrombin generation depends on the mutually
stimulatory interactions of platelet activation and coagula-
tion,21 and that integrin IIb3 activation significantly con-
tributes to platelet-dependent thrombin generation.31 Thus, as
proposed earlier,9 moderate antiplatelet and hypocoagulant
effects of fish oil may add in lowering the thrombogram
curve. From the present results, we can conclude that the fish
oil effect on thrombin generation is enhanced by the presence
of platelets, but that the contribution of integrin activation is
still unclear.
As considerable intersubject variation was observed in
coagulation factor levels and size of the thrombogram, the 25
volunteers were evaluated on the presence of frequent poly-
morphisms in fibrinogen and factor V genes with reported
increased thrombotic risk. Typically, carriers of fibrinogen
-chain 312Ala variant (n10/25) had a higher baseline
fibrinogen level that was accompanied by stronger reduction
in both thrombin generation (ETP) and fibrinogen level with
fish oil than noncarriers. In fact, the fibrinogen reduction in
carriers explained most of the effect on thrombin generation
with or without platelets. In literature, the 312Ala allele
influences clot stability32 and predisposes clots to emboliza-
tion,25 but the relation with fibrinogen expression is still
unclear. This polymorphism is relatively abundant among
whites with an estimated frequency of 35% to 40%.25
However, there was no difference between carriers of com-
mon haplotypes in the promoter region of the -fibrinogen
gene (854/148), which in some, but not all, studies is
linked to increased fibrinogen expression.33
The factor V His1299Arg (A4070G) polymorphism, asso-
ciated with HR2 haplotype, is related with lower factor V
levels.26 The 5 carriers of 1299Arg factor V had lower factor
V levels than the noncarriers, both before and after fish oil
supplementation. Carriers tended to respond better to fish oil,
but group size was too small to validate this.
Figure 3. Effect of fibrinogen and factor V on thrombin genera-
tion. Normal pooled plasma was prepared with variable concen-
trations of human fibrinogen or factor V. Tissue factor-induced
thrombin generation was measured with 4 mol/L phospholipids
at the following conditions: (A) 0% to 110% fibrinogen and
100% factor V; (B) 0% to 110% factor V and 100% fibrinogen.
Curves of nanomolar thrombin concentrations were obtained by
using separate calibrator traces for each different sample to
eliminate differences in light scatter. Indicated factor levels
(compared with normal pooled plasma) were always checked in
the reconstituted plasma samples. Data are representative for 3
or more experiments. Thrombin generation curves with plasmas
from carriers of 1299Arg and His1299 factor V gave the same
factor V dependency.
Figure 4. Effect of fish oil on fibrinogen and factor V levels and
thrombin generation in plasma/phospholipids. A and B, Carriers
of fibrinogen- 312Ala allele (n10 heterozygotes/25). C and D,
Carriers of factor V 1299Arg allele (n5 heterozygotes/25). Data
(meanSE) were obtained as described for Tables 1 and 2.
When fibrinogen was measured as antigen level, 312Ala carriers
also had higher baseline levels than noncarriers (3.700.20 ver-
sus 2.570.19 g/L), and showed a greater reduction after fish
oil (P0.016). *P0.05 (Mann–Whitney).
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In general, limitation, and strength, of this study is that the
effect evaluation was analyzed in samples from a limited
number of 25 individuals with borderline increased body
mass index. This limits the statistical power and precludes the
finding of small effects but, when effects are found, these are
likely to be biologically and medically significant. The small
numbers make it difficult to draw strong conclusions on
differences between the polymorphisms. Yet, this report
provides a first indication that genetic variation can contrib-
ute to a variable hypocoagulant (thromboprotective) fish oil
effect.
Considering that the hypocoagulant effect of in fish oil is
vitamin K-independent and has a genetic component, it is of
interest to speculate on the mechanism of action. In mice,
omega-3 PUFAs can downregulate the hepatic expression of
the sterol regulatory element-binding protein-1 34 and of the
peroxisome proliferator-activated receptor- system.35 Fur-
ther, peroxisome proliferator-activated receptor- controls
fibrinogen levels in humans.36 One possibility, therefore, is
that omega-3 PUFAs provoke hypocoagulant conditions by
influencing transcription systems, in which genetic variation
may play a modulatory role. However, fish oil may also act
on the translation or posttranslation level, eg, altering hepatic
secretion quantitatively or qualitatively.
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